* Bionano Genomics Inc is expected to show a rise in quarterly revenue when it reports results on August 9.
* The San Diego California-based company is expected to report a 24.4% increase in revenue to $8.295 million from $6.67 million a year ago, according to the mean estimate from 5 analysts, based on Refinitiv data. The company's guidance on May 9 2023, for the period ended June 30, was for revenue between $7.80 million and $8.30 million.
* Refinitiv's mean analyst estimate for Bionano Genomics Inc is for a loss of $1.03 per share.
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Bionano Genomics Inc is $30, above its last closing price of $4.67.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -1.10 -1.10 -1.20 Missed -9.1
Dec. 31 2023 -1.14 -1.10 -1.30 Missed -18.2
Sep. 30 2022 -1.18 -1.15 -1.10 Beat 4.3
Jun. 30 2022 -1.03 -0.91 -1.10 Missed -20.4
Mar. -0.87 -0.75 -1.10 Missed -46.7
31 2022
Dec. 31 2021 -0.64 -0.65 -0.80 Missed -23.6
Sep. 30 2021 -0.57 -0.57 -0.74 Missed -30.6
Jun. 30 2021 -0.46 -0.45 -0.60 Missed -32.6
This summary was machine generated August 8 at 02:05 GMT. All figures in US dollars unless otherwise stated.